Humacyte (HUMA) Cost of Revenue (2025 - 2026)
Humacyte (HUMA) reported Cost of Revenue of $2.0 million for Q1 2026, up 1286.39% year-over-year from $147000.0 in Q1 2025, and down 77.56% quarter-over-quarter from $9.1 million in Q4 2025.
Humacyte (HUMA) Cost of Revenue (2025 - 2026) Analysis & Trends
Humacyte (HUMA) has 2 years of Cost of Revenue data on file, last reported at $2.0 million in Q1 2026.
- Cost of Revenue for Q1 2026 came in at $2.0 million, up 1286.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.6 million (up 7786.39% YoY), and the FY2025 annual result was $9.7 million, changed N/A from the prior year.
- Cost of Revenue slipped to $2.0 million in Q1 2026 per HUMA's latest filing, from $9.1 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $9.1 million in Q4 2025 and troughed at $147000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 2.05 Mn |
| 10 | Humacyte | 267.09 Mn | 218.55 Mn | -1.54 Mn | 2.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.04 Mn |
| Mar 31, 2026 | 2.04 Mn |
| Dec 31, 2025 | 9.08 Mn |
| Dec 31, 2025 | 9.08 Mn |
| Sep 30, 2025 | 260,000.00 |
| Sep 30, 2025 | 260,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Mar 31, 2025 | 147,000.00 |